C1QTNF9 (C1q and TNF-related protein 9) is an adipokine that activates AMPK, AKT, and p44/42 MAPK signaling pathways [UniProt]. The protein functions as both an autocrine myokine and endocrine factor with pleiotropic roles across multiple tissues. In skeletal muscle, CTRP9 expression declines with aging and cellular senescence 1. The protein promotes myogenic differentiation while suppressing atrophy-related genes through the LAMP2A/NLRP3 axis, enhancing chaperone-mediated autophagy and reducing inflammatory stress 1. In cardiac tissue, CTRP9 is primarily secreted by myocardial capillary endothelial cells and promotes maladaptive remodeling via ERK5-mediated GATA4 activation, contributing to cardiac hypertrophy and dysfunction 2. Conversely, CTRP9 mediates cardioprotective effects in right ventricular cardiomyocytes through AMPK-dependent induction of anti-oxidant enzymes, reducing reactive oxygen species and apoptosis 3. CTRP9 exhibits anti-inflammatory properties relevant to wound healing; it promotes diabetic wound healing by enhancing dendritic cell efferocytosis via the ATF3/SLC7A11 axis 4. Reduced CTRP9 expression is associated with impaired healing in diabetic wounds and metabolic dysfunction in adolescents with type 2 diabetes 5. Clinically, C1QTNF9 is identified as a prognostic biomarker in pancreatic ductal adenocarcinoma, contributing to pyroptosis and inflammasome-related risk stratification 6.